Mezigdomide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Mezigdomide
- DrugBank Accession Number
- DB17584
- Background
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 567.621
Monoisotopic: 567.228182629 - Chemical Formula
- C32H30FN5O4
- Synonyms
- 4-(4-((4-(((2-((3s)-2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1h-isoindol-4- yl)oxy)methyl)phenyl)methyl)piperazin-1-yl)-3-fluorobenzonitrile
- Benzonitrile, 4-(4-((4-(((2-((3s)-2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1h-isoindol-4-yl)oxy)methyl)phenyl)methyl)-1-piperazinyl)-3-fluoro-
- External IDs
- CC-92480
- CC92480
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LA88IH4O02
- CAS number
- 2259648-80-9
- InChI Key
- YTINZZFBHWSAGL-NDEPHWFRSA-N
- InChI
- InChI=1S/C32H30FN5O4/c33-26-16-23(17-34)8-9-27(26)37-14-12-36(13-15-37)18-21-4-6-22(7-5-21)20-42-29-3-1-2-24-25(29)19-38(32(24)41)28-10-11-30(39)35-31(28)40/h1-9,16,28H,10-15,18-20H2,(H,35,39,40)/t28-/m0/s1
- IUPAC Name
- 4-[4-({4-[({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)methyl]phenyl}methyl)piperazin-1-yl]-3-fluorobenzonitrile
- SMILES
- FC1=CC(=CC=C1N1CCN(CC2=CC=C(COC3=CC=CC4=C3CN([C@H]3CCC(=O)NC3=O)C4=O)C=C2)CC1)C#N
References
- General References
- Not Available
- External Links
- ChemSpider
- 84451594
- ChEMBL
- CHEMBL4648616
- PDBe Ligand
- QFC
- PDB Entries
- 8d7u / 8d7v / 8d7w / 8d7z
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Relapsed/Refractory Multiple Myeloma (RRMM) 2 1 Completed Other Healthy Volunteers (HV) 2 1 Completed Treatment Healthy Volunteers (HV) 3 1 Completed Treatment Hepatic Impairment 1 1 Not Yet Recruiting Treatment Impaired Renal Function 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 3.37 Chemaxon pKa (Strongest Acidic) 11.61 Chemaxon pKa (Strongest Basic) 7.18 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 105.98 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 155.7 m3·mol-1 Chemaxon Polarizability 59.67 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at March 04, 2023 05:45 / Updated at March 05, 2023 10:00